Asensus Surgical (Asensus Surgical) Change In Receivables : $0.55 Mil (TTM As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Asensus Surgical Change In Receivables?

Asensus Surgical's change in receivables for the quarter that ended in Mar. 2024 was $2.78 Mil. It means Asensus Surgical's Accounts Receivable declined by $2.78 Mil from Dec. 2023 to Mar. 2024 .

Asensus Surgical's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.62 Mil. It means Asensus Surgical's Accounts Receivable increased by $0.62 Mil from Dec. 2022 to Dec. 2023 .

Asensus Surgical's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.68 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Asensus Surgical's Days Sales Outstanding for the three months ended in Mar. 2024 was 54.85.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Asensus Surgical's liquidation value for the three months ended in Mar. 2024 was $-16.32 Mil.

Asensus Surgical Change In Receivables Historical Data

The historical data trend for Asensus Surgical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical Change In Receivables Chart

Asensus Surgical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

6.08

-0.45

-1.14

-0.77

-0.62

Asensus Surgical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															1.61	0.01	0.53	-2.77	2.78

Asensus Surgical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.55 Mil.

Asensus Surgical (AMEX:ASXC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Asensus Surgical's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.675	/	1.123	*	91
=	54.85

2. In Ben Graham's calculation of liquidation value, Asensus Surgical's accounts receivable are only considered to be worth 75% of book value:

Asensus Surgical's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	7.989	-	27.79	+	0.75 * 0.675	+	0.5 * 5.958
=	-16.32

Asensus Surgical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Asensus Surgical (Asensus Surgical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (AMEX:ASXC) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

2TX:Germany

Address

1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703

Website

https://www.asensus.com

Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.

Executives

Starling William N Jr	director	2300 BUCKSKIN ROAD, POCATELLO ID 83201
Andrea Biffi	director	C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060
Elizabeth Kwo	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
David Bruce Milne	director	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Kevin J Hobert	director	343 STATE STREET, ROCHESTER NY 14650
Fernando Anthony C. J.	officer: Chief Technology Officer	635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Rampertab Shameze	officer: EVP, Chief Financial Officer	C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108
Brett Farabaugh	officer: Interim CFO	108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
Joseph P Slattery	officer: EVP and CFO	C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Eric A Smith	officer: Chief Commercial Officer	7 CALEB CIRCLE, SAN ANTONIO TX 78258
Todd Pope	director, officer: President and CEO	C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713
Willam N Kelley	director	MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Sofar, S.p.a	10 percent owner	VIA FIRENZE 40, TREZZANO ROSA L6 20060
Andrew N Schiff	director, 10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022